HOLON, Israel, April 2, 2018 /PRNewswire/ — Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of bi-specific and multi-specific immuno-oncology antibody products. …
Original Article: Compugen Enters Exclusive License Agreement with MedImmune for Bi-Specific and Multi-Specific Antibody Products